| Name | Tucidinostat |
| Description | Tucidinostat (Chidamide) is an effective and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8/11 (IC50: 733/432 nM), and shows no effect on HDAC4/5/6/7/9. |
| In vitro | Tucidinostat shows potent antitumor activity and inhibits several human-derived tumour cell lines, such as HL-60, U2OS, LNCaP with GI50s of 0.4 ± 0.1, 2.0 ± 0.6, and 4.0 ± 1.2 μM, respectively. In addition, Tucidinostat shows less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCCHEL)[1]. |
| In vivo | Tucidinostat, administered orally at doses ranging from 12.5 to 50 mg/kg, effectively and dose-dependently decreases tumor size and weight in mice afflicted with various carcinomas including HCT-8 colorectal, A549 lung, BEL-7402 liver, and MCF-7 breast, without any significant loss in body weight[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6 mg/mL (15.37 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
DMSO : 60 mg/mL (153.68 mM)
Ethanol : 1 mg/mL
|
| Keywords | HDAC | HBI 8000 | CS055 | Histone deacetylases | Tucidinostat | Inhibitor | inhibit | HBI8000 | CS-055 |
| Inhibitors Related | Sodium 4-phenylbutyrate | Curcumin |
| Related Compound Libraries | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
